Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Opposition Party Plans State Owned Generics Company

Executive Summary

The UK’s main opposition party is proposing to create a publicly owned generics company, should it win the next general election.

You may also be interested in...



UK Opposition Party Wants Compulsory Licenses For ‘Extortionate’ Medicines

The UK’s main opposition party says it would use compulsory licensing to ensure access to “extortionately” priced medicines. Unsurprisingly, the responses are polarized.

Dutch Move On Pharmacy Compounding Could Deter Orphan Drug Launches

Medicines prepared in pharmacies are now exempt from patent law in the Netherlands, giving pharmacists greater scope to prepare their own versions of patented medicines.

Brazilian HTA To Adopt Cost-Effectiveness Thresholds

Brazil’s health technology assessment institute is to incorporate cost-effectiveness thresholds into its decision making.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS140909

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel